Current treatment of acute leukemia

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Background:

• Accurate risk stratification is essential for optimizing treatment strategies in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
• Current therapeutic approaches require refinement to address specific challenges in different patient subgroups.
• Understanding the biology of leukemic cells and their interaction with the bone marrow microenvironment is critical for improving outcomes.

Purpose of the Study:

• To delineate the distinct therapeutic needs for standard-risk and high-risk ALL patients.
• To identify strategies for overcoming early drug resistance in high-risk ALL.
• To enhance remission induction and maintenance in acute myeloid leukemia (AML).

Main Methods:

• This study reviews current therapeutic paradigms and identifies key challenges in managing ALL and AML.
• It emphasizes the need for risk-specific treatment protocols.
• The review highlights the importance of understanding drug resistance mechanisms and marrow microenvironment interactions.

Main Results:

• Standard-risk ALL patients require therapies balancing efficacy with minimal toxicity due to long life expectancy.
• High-risk ALL necessitates novel approaches to prevent or overcome rapid acquisition of drug resistance.
• AML treatment requires improved remission induction and, critically, sustained remission maintenance.

Conclusions:

• Effective management of ALL and AML hinges on precise risk stratification and tailored therapeutic interventions.
• Addressing drug resistance in high-risk ALL and optimizing remission maintenance in AML are paramount for improving patient survival.
• Further research into the interplay between leukemic and normal marrow elements is crucial for advancing AML therapy.